The distribution of medications into the relevant layers of the skin is referred to as dermal delivery. The delivery pathway has the potential to improve the active ingredients’ local bioavailability at their drug target. Nanocrystal-based formulations for dermal distribution have recently received a lot of attention due to their increased skin penetration. According to current research on nanocrystal for topical delivery, it could be a novel approach for all formulators struggling with poorly soluble drugs. Nanocrystals are a step forward from typical nanocarriers, offering 100 percent drug loading, a huge surface area, and the potential for follicular targeting. The skin structure and physiology, nanocrystal fabrication methods, and applications are discussed in this review.

This paper presents the Parkinson “Parkinson detector” application, which was developed in the Android environment and which should provide a modest contribution to the timely detection of the initial symptoms of Parkinson’s disease. The application was developed for a smartphone, commercially available to everyone and using existing, already built-in sensors, gyroscopes, and accelerometers. The development of the application „Parkinson Detector“ is intended for use on smartphones to control the condition of the human body, as well as prevention and signaling in case of detection of the initial state of the disease. In time detection of such severe degenerative diseases as Parkinson’s disease (PD) would enable the timely application of therapy and improve the chances of care and control of the disease, because currently, PD is diagnosed when wide areas of the brain are already damaged, motor symptoms of patients are evident and begin to influence their common activities. We believe that the use of the application „Parkinson Detector“ can help improve the quality of life, especially in the elderly.

Patients suffering from arrhythmias, bradycardia or chronic atrial arrhythmia with high degree blocks faced complications associated with transvenous pacemaker specially with old techniques which involved subcutaneous pocket, bleeding, infection and even a pneumothorax during surgical placement of pacemaker can be overcome by using leadless pacemaker. In 2013, the first leadless pacemaker was introduced in international clinical trials but removed from market due to its premature battery exhaustion. Then it redesigned with key design improvements. The leadless ll phase 2 trial then approved by FDA (Food and Drug Administration) on March 31^st, 2022. In trials study included 200 subjects across 43 sites in different countries. Procedures were performed without endotracheal intubation. The objective of this study was to evaluate the success of implantation, its performance and preclinical studies. In phase ll implantation success was 98%. Unique aspects of this device were improved implant success rate and low repositioning rates. The new design of leadless pacemaker is with dual – helix fixation mechanism which is specific to right atrium anatomy. The avier leadless pacemaker contains following components:

• The avier leadless pacemaker [LSP112V]
• Avier delivery system catheter [LSCD111]
• Avier link module [Model LSL02]

It is conditionally safe for use in MRI environment by following up proper instructions. The avier leadless pacemaker met its all safety and efficacy end points. Patients who have poorly integrated hardware such as drivelines, comorbidities associated with discomfort and infection. Experts predicted that advancement in transcutaneous charging capabilities will soon render large devices which may be completely implantable.

FDA has approvecamyzyos (mavacamten) capsule. The main aim of camyzyos drug to treat obstructive hypertrophic cardiomyopathy (oHCM). Camyzyos, first and only FDA approved drug that inhibit the myosin inhibitor. camyzyos available in various range like, 2.5mg, 5mg, 10mg, 15mg, capsules for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy. Mavacamten is a targeted inhibitor of cardiac myosin that reduces the number of myosin actin cross bridge and decreases contractility. Mavacamten is selective allosteric modulator of cardiac myosin ATPase. Currently available pharmacological symptoms of oHCM are not disease specific. oHCM is a monogenic C.V disorder that often goes undiagnosed and can provide a variety of symptoms like, shortness of birth, it causes sudden cardiac death. oHCM mainly causes due to excessive contraction of the left ventricle. In patients, camyzyos decrease the pressure gradient contributing to obstruction of VLOT.
Mavacamten trail show that mavacamten was superior to placebo at improving exercise capacity of health status. Some patients who take placebo HCM feel better, and some other patients develop side effects, but in the case of mavacamten try to give best pharmacological action, rarely produce side effect.